MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022." Nature Methods had recognized the impact of long-read sequencing in a variety of groundbreaking studies, including those leveraging PacBio technology from the Vertebrate Genome Project, Telomere-to-Telomere Consortium, and Human Pangeome Reference Consortium, among others.

"PacBio has led a transformation of genomics by making long-read sequencing more accurate and accessible than ever with the introduction of HiFi sequencing," said Christian Henry, President and Chief Executive Officer of PacBio. "Nature Methods recognizes the criticality of highly accurate long-read sequencing to continuing to advance genomic research. We believe that our customers' use of the high-throughput Revio system, which we expect to begin shipping in the first quarter of 2023, will result in a dramatic increase in the use of long-read sequencing to power new studies." 

The Revio system, which will use the same highly accurate HiFi chemistry as PacBio's Sequel instrument line, is designed to provide 20kb+ sequencing reads with >99.9% accuracy, uniform coverage, extraordinary application performance for variant calling and assembly, and DNA methylation detection.

Nature Methods cited four wish-list items which further long-read sequencing: lower cost, greater accuracy, time savings, and increased application utility. We believe the Revio system will deliver on this wish list by offering higher accuracy, better economics, faster speed, and increased throughput capabilities, along with the ability to address large-scale genomics projects once considered impractical with current technologies on the market. The Revio system has been designed to allow PacBio customers to do more science on a single instrument and to sequence up to 1,300 human whole genomes per year for less than $1,000 per genome.

For more insights on the future of long-read sequencing, review Nature Methods news feature which includes insights from key genomics opinion leaders and listen to Nature Methods editor Vivien Marx, interview PacBio Co-Founder and Chief Scientific Officer Jonas Korlach, PhD, about the evolution and continuing importance of long-read sequencing and PacBio's ongoing collaboration with our customers on her podcast Conversations with Scientists.

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB™ short read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to: future availability, uses, accuracy, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including the Revio sequencing system; customers' ability to scale HiFi sequencing through the use of Revio; throughput, accuracy, affordability, coverage, run times, data, density, cost per genome, pricing, and number of genomes that can be sequenced per year; improvements in yield and accuracy; expected delivery timeframe, and other future events. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this press release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements, including, among others, challenges inherent in developing, manufacturing, launching, marketing and selling new products, and achieving anticipated new sales; assumptions, risks and uncertainties related to the ability to attract new customers and retain and grow sales from existing customers; potential product performance and quality issues and potential delays in commercialization timelines; rapidly changing technologies and extensive competition in genomic sequencing that could make the products PacBio is developing obsolete or non-competitive; supply chain risks; successfully completing development of a product that is not yet commercially available; customers and prospective customers curtailing or suspending activities utilizing our products; the impact of U.S. export restrictions on the shipment of PacBio products to certain countries; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Readers are strongly encouraged to read the full cautionary statements contained in PacBio's filings with the Securities and Exchange Commission, including the risks set forth in the company's Forms 8-K, 10-K, and 10-Q. PacBio disclaims any obligation to update or revise any forward-looking statements.

Contacts

Investors:
Todd Friedman
650.521.8450
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media:
Lizelda Lopez
This email address is being protected from spambots. You need JavaScript enabled to view it.